This cancer can show up in any part of the lung. It usually grows and spreads rapidly, which makes treatment a challenge. A type of large-cell carcinoma, called large-cell neuroendocrine carcinoma ...

Within the first 3 years following surgery, a chest x-ray and computed tomography scan were performed ... On the basis of data from the Adjuvant Lung Cancer Project Italy (ALPI), 12 PFS rate at 3 ...

Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer. Although studies identified ...

A phase IIa study of ABT-263 in patients with relapsed small-cell lung cancer (SCLC). Background: To compare the presenting and prognostic characteristics, cause-specific survival (CSS) rates, and ...

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad ...

Non-small-cell lung cancer ... by cancer cells that grow and spread in different ways. The three most common forms of NSCLC are adenocarcinoma, squamous cell carcinoma and large cell carcinoma.

Small cell lung cancer, or SCLC, is aggressive ... reflection of our proven ability to make landmark breakthroughs and our trusted ability to lead large scientific collaborations. “What we wanted to ...

Advanced biliary tract cancer (BTC) includes cholangiocarcinoma, gallbladder carcinoma ... a resource that fills this gap: a large panel of patient-derived cell lines coupled with integrative ...

May 14 (Reuters) - The U.S. Food and Drug Administration has approved AbbVie's (ABBV.N), opens new tab drug to treat adults with a type of lung cancer who have received previous treatment, the ...

NSCLC can be further subdivided into: lung adenocarcinoma (ADC), large cell carcinoma and squamous cell carcinoma (SCC). These cancer subtypes have distinct morphologies and molecular profiles ...

There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...